VTP in the focal therapy of low-risk, localized prostate cancer

We have previously reported data from the 2-year follow-up of the patients participating in the PCM301 trial of vascular targeted phototherapy (VTP) — a form of prostate hemiablation — compared to active surveillance in the treatment of low-risk, localized prostate cancer. New data at 4 years of follow-up have now been published in the Journal of Urology. … READ MORE …

Tookad-Soluble + VTP effective and safe in treatment of low-risk prostate cancer

Another new media report (based on data just published in Lancet Oncology) states that “vascular-targeted photodynamic therapy” or VTP in combination with an experimental drug called padeliporfin or WST11 can be used to successfully treat low-risk prostate cancer. … READ MORE …

Data from a small US trial of the TOOKAD VTP system in low-risk disease

Earlier this year we reported data from a randomized, 400-patient trial in Europe of TOOKAD® Soluble vascular targeted photodynamic therapy (VTP) with the proprietary drug WST11. … READ MORE …

New form of focal therapy approved for treatment of low-risk prostate cancer

According to information released to the media on January 4 this year (which we have only now had brought to our attention) a combination of drug therapy with laser ablation has been approved  “for the focal treatment of early stage prostate cancer.” … READ MORE …